INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/001333

A.	CLASSIFICATION OF SUBJECT MATTI	CR	_		
Int. Cl. 7:	A61K 39/00, A61P 37/02				
According to	International Patent Classification (IPC) or to b	ooth national classification and IPC			
В.	FIELDS SEARCHED				
Minimum docu	mentation searched (classification system followed	by classification symbols)			
Documentation	searched other than minimum documentation to the	extent that such documents are included in the fields search	hed		
DWPI, Medl Hyperimmur	line; Keywords; Tolerance, Modulation, Sl nization, Adjuvant, Antigen, Secondary An	e of data base and, where practicable, search terms used) kew, Alter, Immune, Th1, Th2, Hyperimmunisati tigen Challenge, Oral Tolerance, Alum, Freud, A rosis, thyroiditis, Crohn's disease, systemic lupus	Muminum		
С.	DOCUMENTS CONSIDERED TO BE RELEVA	ANT			
Category*	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.		
,	T helper cell type 1 responses to soluble	septor monoclonal antibody is an adjuvant for antigen only in the presence of wember 2000, vol 192, No. 10, pages 1529-			
X	Abstract, Material and Methods, figure 2	2	1-51		
		arrogate the induction of oral tolerance of , 2000, Scand. J Immunol, vol 51, pages 454-			
X	Abstract, Material and Methods		1-51		
X F	I urther documents are listed in the continua	tion of Box C X See patent family anne	ex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance or theory underlying the invention "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority "T" later document published after the international filing date and not in conflict with the application but cited to underst or theory underlying the invention "X" document of particular relevance; the claimed invention can be considered to involve an in when the document is taken alone "Y" document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in when the document of particular relevance; the claimed invention can be considered to involve and in the conflict with the application but cited to understance and not invention can be considered to involve and invention can					
claim(s) publicat	or which is cited to establish the ion date of another citation or other special as specified)	considered to involve an inventive step when the docume with one or more other such documents, such combinatio a person skilled in the art	ent is combined		
"O" document exhibition "P" document	nt referring to an oral disclosure, use, "&" on or other means nt published prior to the international filing	document member of the same patent family			
	later than the priority date claimed al completion of the international search	Date of mailing of the international search report			
21 October 2	-	2 7 OCT 2004			
	ng address of the ISA/AU	Authorized officer			
PO BOX 200, W B-mail address: ;	PATENT OFFICE VODEN ACT 2606, AUSTRALIA pct@ipaustralia.gov.au	ANTHONY MURFETT			
Facsimile No. (02) 6285 3929	Telephone No : (02) 6283 2243	ľ		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/001333

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	02
Wu X et al, "Selective suppression of antigen-specific Th2 cells by continuous microdose oral tolerance", Eur J Immunol, Jan 1998, vol 28, pages 134-142.	3
Abstract, Material and Methods	1-51
Jilek S et al, "Antigen-independent suppression of the allergic immune response to bee	,
venom phospholipase A2 by DNA vaccination in CBA/J mice", J Immunol, 2001, vol 166, pages 3612-3621	
Abstract, page 3613 left column paragraph 5 - right column paragraph 3, figure 3	1-51
Melamed D et al, "Peripheral tolerance of Th2 lymphocytes induced by continuous	
	1-51
	1-51
vol 18(6), pages 854-858.	
Abstract, Material and Methods	1-51
von Herrath MG et al, "Tolerance Induction with Agonist Peptides Recognized by	
Abstract, "peptide and immunization schedules" page 194	31-36, 51
Moreland I.W et al. "T Cell Recentor Pentide Vaccination in Rheumatoid Arthritis"	_
Arthritis and Rheumatism, November 1998, vol 41, no 11, pages 1919-1929.	
Abstract	31, 35-36, 5
WO 2001/052886 A (Alfred Hospital et al) 26 July 2001	•
Abstract, page 19 lines 14-31	35-36, 51
Tobagus IT et al. "Adjuvant costimulation during secondary antigen challenge directs	
qualitative aspects of oral tolerance induction, particularly during neonatal period",	
	1-51
2 - 1 - 1 - 2 - 1 - 1 - 1 - 1 - 1 - 1 -	
	Jilek S et al, "Antigen-independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice", J Immunol, 2001, vol 166, pages 3612-3621 Abstract, page 3613 left column paragraph 5 - right column paragraph 3, figure 3 Melamed D et al, "Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbimun", Int Immunol, May 1996, vol 8, no 5, pages 717-724. Abstract, Table 3, Material and Methods Kim JH and Ohsawa M, "Oral tolerance in ovalbumin in mice as a model for detecting modulators of the immunologic tolerance to a specific antigen", Biol Pharm Bull, 1995, vol 18(6), pages 854-858. Abstract, Material and Methods von Herrath MG et al, "Tolerance Induction with Agonist Peptides Recognized by Autoaggressive Lymphocytes is Transient: Therapeutic Potential for Type 1 Diabetes is Limited and Depends on Time-point of Administration, Choice of Epitope and Adjuvant", J Autoimmun, May 2001, 16(3), page 193-9 Abstract, "peptide and immunization schedules" page 194 Moreland LW et al, "T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis", Arthritis and Rheumatism, November 1998, vol 41, no 11, pages 1919-1929. Abstract WO 2001/052886 A (Alfred Hospital et al) 26 July 2001 Abstract, page 19 lines 14-31 Tobagus IT et al, "Adjuvant costimulation during secondary antigen challenge directs

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No. PCT/AU2004/001333

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	•	Patent Family Member						
WO 0152886	AU	26573/01	CA	2402831	EP	1409011		
	US	2003191076	ZA	200206657				

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX